论文部分内容阅读
[目的]采用系统评价的方法探索体重丢失对胰腺癌患者预后及相关临床特征的影响。[方法]检索Pubmed、SCI-Ex-panded、Embase、Cochrane图书馆、中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、维普中文科技期刊数据库(VIP)及万方数据知识服务平台(Wanfang Data Knowledge Service Platform)中有关体重丢失与胰腺癌患者预后及临床特征关系的文献;根据NOS文献质量评估标准评估纳入文献质量;采用RevMan5.3软件进行数据综合;根据异质性大小决定采用固定或随机效应模型;同时对未纳入meta分析的文献进行描述分析。[结果]共18篇文献符合纳入标准,6篇(861例)可行meta分析。其中体重丢失≥10%的患者(188例)与体重丢失<10%的患者(264例)相比,两组OS的合并风险比(hazard ratio,HR)为2.66(95%CI:1.49~4.76,P=0.0009;异质性P=0.009,I2=74%);体重丢失≥5%的290例患者与体重丢失<5%的181例患者相比,两组OS的合并HR为1.83(95%CI:0.61~5.47,P=0.28;异质性P<0.00001,I2=94%);研究同时指出体重丢失与患者的PFS、MST、生存率、住院时间及肿瘤临床特征也有一定的相关性。[结论 ]较大程度的体重丢失将缩短胰腺癌患者的OS,影响患者的PFS、MST、住院时间、肿瘤临床特征及机体功能状态等。
[Objective] To evaluate the impact of body weight loss on the prognosis and related clinical features of patients with pancreatic cancer by systematic evaluation. [Method] Pubmed, Publish, SCI-Ex-panded, Embase, Cochrane Library, CNKI, CBM, VIP and Wanfang Data Knowledge Service Platform (Wanfang Data Knowledge Service Platform) literature on the relationship between weight loss and prognosis and clinical features of patients with pancreatic cancer; quality of the included literature assessed according to NOS literature quality assessment criteria; RevMan5.3 software for data synthesis; and determination of heterogeneity Fixed or random effects model; at the same time do not include meta-analysis of the literature description analysis. [Results] A total of 18 articles met the inclusion criteria and 6 articles (861 cases) were feasible meta-analysis. The hazard ratio (HR) was 2.66 (95% CI: 1.49 to 4.76) in patients with weight loss ≥10% (188 patients) and patients with less than 10% weight loss (264 patients) , P = 0.0009; heterogeneity P = 0.009, I2 = 74%); 290 patients who lost 5% or more of body weight had a combined HR of 1.83 compared with 181 patients who lost <5% % CI: 0.61-5.47, P = 0.28; heterogeneity P <0.00001, I2 = 94%). The study also pointed out that the loss of body weight correlated with the PFS, MST, survival rate, hospitalization time and the clinical features of the tumor . [Conclusion] A large loss of body weight will shorten the OS of patients with pancreatic cancer and affect the PFS, MST, length of hospital stay, tumor clinical features and body function status.